Document is current
Any future updates will be listed below
-
Authors
Iki, Masayuki https://orcid.org/0000-0003-2128-5255
Fujimori, Kenji
Okimoto, Nobukazu
Nakatoh, Shinichi
Tamaki, Junko
Ishii, Shigeyuki
Imano, Hironori
Ogawa, Sumito
-
Funding
Funding for this research was provided by:
Taiju Life Social Welfare Foundation (52nd Taiju Life Social Welfare Foundation Research Grant 2019)
Japan Osteoporosis Foundation (Japan Osteoporosis Foundation Grant for Bone Research 2019)
Pfizer Health Research Foundation (28th Pfizer Health Research Grant 2019)
- License Information
-
More Information
Article History
Received: 24 December 2024
Accepted: 30 December 2024
First Online: 14 January 2025
Declarations
:
: Nobukazu Okimoto has received consulting fees from Asahi-Kasei Pharmaceutical Co., Ltd. and Teijin Pharma Ltd., and payments for lectures, including speakers’ bureau fees, from Asahi-Kasei Pharmaceutical Co., Ltd., Amgen K.K., Daiichi-Sankyo Co., Ltd., and Teijin Pharma Ltd. Shinichi Nakatoh has received payments for lectures, including speakers’ bureau fees, from Asahi-Kasei Pharmaceutical Co., Ltd., Amgen K.K., and Daiichi-Sankyo Co., Ltd. Shigeyuki Ishii has received honorarium from Teijin Pharma Ltd., and has written manuscripts for Teijin Pharma Ltd. Masayuki Iki, Kenji Fujimori, Junko Tamaki, Hironori Imano, and Sumito Ogawa declare that they have no conflict of interest.
